Functional Peptides Target Veterinary Osteoarthritis, but Clinical Evidence Remains Uneven

Oral collagen-derived peptides have produced encouraging signals in naturally occurring osteoarthritis in dogs and horses, but a 2026 narrative review concludes that most sequence-defined peptide therapies remain preclinical and do not yet qualify as disease-modifying treatments. The review found the strongest direct veterinary evidence for oral bioactive collagen products, whereas more sophisticated anti-inflammatory, chondrogenic and cartilage-targeting peptides have mainly been tested in human cells, rodents or induced animal models. This imbalance leaves functional peptides a plausible route to disease modification, but not an established replacement for current multimodal care.

Veterinary osteoarthritis is a whole-joint disorder rather than simple wear of articular cartilage. Chondrocyte dysfunction, synovitis, altered biomechanics, subchondral bone remodeling, osteophyte formation and peripheral or central sensitization can reinforce one another. The resulting disease causes pain, impaired gait, reduced activity and diminished quality of life in companion and performance animals. Available management—including weight control, rehabilitation, exercise modification, non-steroidal anti-inflammatory drugs, the EP4 receptor antagonist grapiprant and anti-nerve growth factor antibodies—can improve symptoms, but generally does not restore cartilage extracellular matrix or demonstrate sustained protection from structural deterioration.

That distinction separates symptom modification from disease modification. The review applies the latter term strictly to an intervention that alters underlying osteoarthritis pathology and slows, prevents or reverses structural joint deterioration while providing clinically meaningful benefit. Better pain scores or gait without evidence about structural progression are therefore insufficient. No peptide-based veterinary osteoarthritis product currently meets that standard. Functional peptides are interesting because their amino-acid sequences can be selected to inhibit inflammatory or matrix-degrading pathways, imitate extracellular-matrix signals, or direct cargo toward damaged joint tissue. The review separates these rational candidates from collagen hydrolysates, which are heterogeneous mixtures whose effects cannot automatically be attributed to one sequence.

Among collagen-derived products, the most detailed canine trial followed 31 client-owned dogs with spontaneously occurring osteoarthritis for 12 weeks. Participants received approximately 240 ± 95 milligrams per kilogram of body weight of a specific porcine type I collagen hydrolysate daily, with omega-3 fatty acid plus vitamin E and placebo groups serving as comparators. Investigators reported improvements in selected force-plate gait variables and owner-assessed quality of life, while spontaneous activity and pain scores did not improve consistently. The result supports a clinically relevant adjunctive signal, but the small sample, predominantly mild-to-moderate disease, short duration, absence of cartilage endpoints and manufacturer support constrain interpretation. Related supplementation studies in 38 horses with mild-to-moderate osteoarthritis reported improvements in several lameness, flexion-pain and mobility measures over 12 weeks, although a pilot two-center design, unequal comparator structure and reliance on subjective outcomes limited certainty.

Sequence-defined peptides offer more precise mechanisms but have yet to close the translational gap. In human chondrocytes stimulated with interleukin-1 beta, the hyaluronan-binding peptide P15-1 combined with high-molecular-weight hyaluronan reduced inflammatory and catabolic responses and supported the pericellular matrix, partly through modulation of p38 mitogen-activated protein kinase signaling. The bone morphogenetic protein receptor-mimetic peptide CK2.1, linked to approximately seven-day hyaluronan-hydrogel release, increased types II and IX collagen and reduced hypertrophic type X collagen in a mouse destabilization-of-the-medial-meniscus model. These studies show biological promise, but neither established target-species pharmacokinetics, repeated-dose safety or benefit in naturally occurring veterinary osteoarthritis.

Delivery may ultimately determine whether peptide activity reaches the intended tissue. Small peptides can be cleared rapidly from synovial fluid, while negatively charged, dense cartilage restricts penetration. Type II collagen-binding, damaged-collagen-binding, aggrecan-associated and receptor-targeting sequences have therefore been attached to nanoparticles, liposomes, polymers, hydrogels, hyaluronic-acid constructs or imaging agents. A WYRGRL-modified nanocarrier improved cartilage localization and delayed degeneration in a rat anterior cruciate ligament transection model; collagen-binding motifs improved retention of hyaluronic-acid constructs in human osteoarthritic cartilage, rats and minipigs; and collagen-hybridizing peptides prolonged retention of a fluorescent payload in rat knees. These findings demonstrate targeting or retention, not stand-alone therapeutic efficacy, because attached drugs, carriers, cells and physical stimuli can confound the peptide’s contribution.

Species-specific biology adds another obstacle. Dogs, cats, horses and rodents differ in joint volume, cartilage thickness, loading, metabolism, lymphatic clearance and feasible intra-articular dose. A ligand that works in a small rodent joint may penetrate or persist differently in a canine or equine joint. Feline osteoarthritis is particularly difficult to recognize: radiographs showed degenerative joint disease in 90% of 100 cats older than 12 years, while a prospective study of 100 client-owned cats aged at least six years found appendicular osteoarthritis in 61% and involvement of more than one joint in 48%. Because cats may show reduced jumping, altered stair use, less grooming or changed exploratory behavior rather than obvious lameness, feline trials may need small-volume or long-acting formulations, target-species pharmacokinetic and safety studies, validated owner-reported mobility measures and objective activity monitoring.

The proposed development path therefore moves from identity, potency and non-cytotoxicity to target-species cells, joint explants, pharmacokinetics, induced disease models and naturally occurring clinical cases. Candidate screening should measure inflammatory, catabolic and anabolic responses, because suppressing inflammation while harming cell viability or matrix production is not a credible advantage. For intra-articular products, researchers must measure intact peptide exposure in synovial fluid and cartilage, residence time and penetration rather than relying on plasma concentrations. Large-animal work needs to quantify active peptide, metabolites, target binding and disease-dependent changes in matrix permeability. Repeated-dose programs must also assess immunogenicity, local irritation, organ toxicity and synovial compatibility, while chemistry, manufacturing and controls must define sequence, purity, potency, degradation products, release behavior and batch consistency.

Clinical trials must then establish benefits that match the intended claim. Force-plate analysis, pressure-sensitive walkways, wearable monitors, range-of-motion measurements and validated owner-reported instruments can assess function, but structural claims also require imaging, biomarkers, histology where feasible or sufficient follow-up to distinguish lasting disease modification from transient analgesia. The review identifies multimodal adjunctive use as the most realistic near-term role, potentially alongside standardized weight management, rehabilitation, non-steroidal anti-inflammatory drugs, EP4 antagonists, bedinvetmab or frunevetmab. Additive efficacy and safety would need prospective testing. The review itself was a targeted narrative appraisal rather than a systematic review or meta-analysis, and publication bias, heterogeneous products, small experimental cohorts, scarce feline evidence and limited independent replication prevent the candidates from being ranked by efficacy. Functional peptides thus offer a versatile but clinically immature platform, with progress depending on demonstrated joint exposure, objective benefit, safe chronic use and structural protection rather than another reduction in an inflammatory marker alone.

Subject of Research: Evaluation of functional peptide therapeutics and delivery systems for veterinary osteoarthritis

Article Title: Functional peptide therapeutics for veterinary osteoarthritis: mechanisms, delivery systems, and translational priorities

Article References: Choi, S.-C., Song, M. G., Yi, S. Y., Lee, S. H., & Lee, I. A. (2026). Functional peptide therapeutics for veterinary osteoarthritis: mechanisms, delivery systems, and translational priorities. Frontiers in Veterinary Science, 13, Article 1974160. https://doi.org/10.3389/fvets.2026.1974160

Image Credits: AI Generated

DOI: 10.3389/fvets.2026.1974160

Keywords: veterinary osteoarthritis, functional peptides, collagen hydrolysates, cartilage targeting, drug delivery, disease modification, canine osteoarthritis, feline osteoarthritis, equine osteoarthritis, Functional, peptide, therapeutics